A randomized controlled study, assessing the safety and immunogenicity of a COVID-19 vaccine in adults
Participants needed: 65+
This study will test the safety and effectiveness of a COVID-19 vaccine candidate.
- 65 years of age or older
- In good health with no immune problems or significant health issues
- Available for follow-up visits for approximately one year at the Canadian Center for Vaccinology in Halifax, NS
What does it involve?
Your participation in the study will involve nine planned visits to CCfV over approximately 14 to 16 months. The will include a screening visit to make sure you are eligible to participate, two vaccination visits (Day 0 and Day 21), four clinic follow-up visits (Day 3, Day 24, Day 42, Day 128 and Day 201), and the final follow-up visit at the end (Day 386). The visits will last from 1-2 hours in duration. In addition, you will be contacted by telephone one day (Day 1 and Day 22) and eight days (Day 8 and Day 29) after each vaccination. After the Day 42 visit, you will be contacted weekly by your preferred method for the monitoring of any COVID-19-related symptoms of interest. If you have such symptoms, you will be asked to come back for one or more additional study visits.
Before any study activities are performed, you will be asked to review and sign the information and consent form